ERBB2 and triple-negative breast carcinoma: Whereas luminal, hormone receptor-expressing tumors, are effectively managed by endocrine therapies at early stages, and patients with HER2-amplified tumors benefit from treatment with HER2-targeted therapies, treatment options for triple-negative breast cancers (TNBC) remain limited to chemo- and radiotherapy [9].